CAR T-cell therapy and critical care : A survival guide for medical emergency teams.

Messmer, Anna S; Que, Yok-Ai; Schankin, Christoph; Banz, Yara; Bacher, Ulrike; Novak, Urban; Pabst, Thomas (2021). CAR T-cell therapy and critical care : A survival guide for medical emergency teams. Wiener klinische Wochenschrift, 133(23-24), pp. 1318-1325. Springer-Verlag 10.1007/s00508-021-01948-2

Preview

Text Messmer2021_Article_CART-cellTherapyAndCriticalCar.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (409kB) | Preview

Chimeric antigen receptor (CAR) T‑cells are genetically engineered to give T‑cells the ability to attack specific cancer cells, and to improve outcome of patients with refractory/relapsed aggressive B‑cell malignancies. To date, several CAR T‑cell products are approved and additional products with similar indication or extended to other malignancies are currently being evaluated. Side effects of CAR T‑cell treatment are potentially severe or even life-threatening immune-related toxicities, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Consequently, medical emergency teams (MET) are increasingly involved in the assessment and management of CAR T‑cell recipients. This article describes the principles of CAR T‑cell therapy and summarizes the main complications and subsequent therapeutic interventions aiming to provide a survival guide for METs with a proposed management algorithm.

Interest & Impact

Downloads

113 since deposited on 08 Nov 2021
43 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item